228 related articles for article (PubMed ID: 16015543)
21. Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
Gopal R
J Support Oncol; 2004; 2(6 Suppl 3):13-7. PubMed ID: 15605920
[TBL] [Abstract][Full Text] [Related]
22. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Arquette M; Wasserman T; Govindan R; Garfield D; Senzer N; Gillenwater H; Socinski M
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):59-61. PubMed ID: 11917286
[TBL] [Abstract][Full Text] [Related]
23. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
[TBL] [Abstract][Full Text] [Related]
24. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Rosenman J
Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
[TBL] [Abstract][Full Text] [Related]
25. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Koukourakis MI; Romanidis K; Froudarakis M; Kyrgias G; Koukourakis GV; Retalis G; Bahlitzanakis N
Br J Cancer; 2002 Aug; 87(4):385-92. PubMed ID: 12177774
[TBL] [Abstract][Full Text] [Related]
26. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
[TBL] [Abstract][Full Text] [Related]
27. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
[TBL] [Abstract][Full Text] [Related]
28. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01.
Movsas B
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):40-5. PubMed ID: 11917283
[TBL] [Abstract][Full Text] [Related]
29. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
[TBL] [Abstract][Full Text] [Related]
30. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Koukourakis MI; Tsoutsou PG; Abatzoglou I
Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
[TBL] [Abstract][Full Text] [Related]
31. Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Werner-Wasik M; Axelrod RS; Friedland DP; Hauck W; Rose LJ; Chapman AE; Grubbs S; Deshields M; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):34-9. PubMed ID: 11917282
[TBL] [Abstract][Full Text] [Related]
32. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
33. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
34. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
[TBL] [Abstract][Full Text] [Related]
36. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
[TBL] [Abstract][Full Text] [Related]
37. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
38. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study.
Willner J; Schmidt M; Kirschner J; Lang S; Borgmeier A; Huber RM; Flentje M
Lung Cancer; 2001 May; 32(2):163-71. PubMed ID: 11325487
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
40. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
